S1P Therapeutics
Blacksburg, US · Founded 2019 · Delaware corporation
S1P Therapeutics is a preclinical-stage biotechnology company developing drugs that target novel nodes in the S1P pathway for treating kidney and autoimmune diseases. Its aim is to create medicines with less toxicity than existing S1P pathway drugs.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 round · 2023
▶$2MraisedJun 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJun 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin LynchExecutive Officer, Director
- Webster SantosExecutive Officer, Director
- Ronald SaycoExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does S1P Therapeutics do?
- S1P Therapeutics is a preclinical-stage biotechnology company developing drugs that target novel nodes in the S1P pathway for treating kidney and autoimmune diseases. Its aim is to create medicines with less toxicity than existing S1P pathway drugs.
- How much funding has S1P Therapeutics raised?
- S1P Therapeutics has disclosed $2M raised across 1 round.
- Where is S1P Therapeutics headquartered?
- S1P Therapeutics is headquartered in Blacksburg, US.